Clinical significance of early hepatocellular carcinoma

Inoue, Kazuto; Takayama, Tadatoshi; Higaki, Tokio; Watanabe, Yoshihiro; Makuuchi, Masatoshi

doi:10.1002/lt.20049

Cited by 30 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our institution, Gd-EOB-DTPA is currently the first choice of contrast agent in liver MR studies for evaluating these lesions, because the HB-phase assists in better diagnosing early HCCs, which have a high chance of being cured and a low risk of recurrence [57,58].…”

Section: Discussionmentioning

confidence: 99%

Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…However, intrahepatic recurrence due to secondary primary HCC is often seen even in patients with early HCC [27, 28]. Takayama et al [25] reported that the 5-year recurrence-free rate was 53 % in patients with early HCC.…”

Section: Discussionmentioning

confidence: 99%

Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy

et al. 2013

View full text Add to dashboard Cite

BackgroundGlypican-3 (GPC3) is a new prognostic factor after curative hepatectomy in patients with hepatocellular carcinoma (HCC), and the expression of GPC3 is known to be associated with postoperative metastasis. However, the role of GPC3 in patients with early HCC remains unknown.MethodsWe retrospectively studied 55 patients with early HCC (total 99 nodules) who underwent initial hepatectomy between 1995 and 2010. Clinicopathological features and surgical outcomes were compared in relation to GPC3 expression.ResultsThe GPC3-positive expression was seen in 28 of 55 patients (50.9 %) with early HCC (44 of 99 nodules). The GPC3-positive expression was significantly associated with hepatitis C virus (HCV) infection (P = 0.0019) and with multiple early HCCs (P < 0.0001). The 5-year disease-free survival rate was significantly lower in patients with GPC3-positive early HCC (27 %) than in patients with GPC3-negative early HCC (62 %, P = 0.0036). The GPC3 expression was a significant independent prognostic factor for disease-free survival. However, it showed no significant difference in overall survival.ConclusionsThe GPC3 expression is capable to be a new prognostic factor for disease-free survival in patients with early HCC.

show abstract

“…Nonetheless, postresection tumor recurrence is common, with a 5-year recurrence rate >50% [1, 2, 11, 12]. In all, 80% of the recurrences develop within the liver remnant [13], so it is important for surgeons to select the most appropriate treatment for patients with recurrent HCC.…”

Section: Discussionmentioning

confidence: 99%

Survival Analysis of Re‐resection Versus Radiofrequency Ablation for Intrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma

et al. 2011

View full text Add to dashboard Cite

BackgroundTumor recurrence after resection of hepatocellular carcinoma is a common phenomenon. Re-resection and radiofrequency ablation (RFA) are good options for treating recurrent HCC. This study compared the efficacy of these two modalities in the treatment of intrahepatic HCC recurrence after hepatectomy.MethodsFrom January 2001 to December 2008, a total of 179 patients developed intrahepatic HCC recurrence after hepatectomy. To treat the recurrence, 29 patients underwent re-resection and 45 patients had RFA. Patient characteristics, clinicopathologic data, and survival outcomes were reviewed.ResultsChild-Pugh status, time to develop first recurrence (12.2 vs. 8.7 months), and recurrent tumor size (2.1 vs. 2.1 cm) were comparable for the two groups. Time to develop a second intrahepatic recurrence after re-resection and RFA was 5.9 and 4.0 months respectively. The 1-, 3-, and 5-year disease-free survival rates were 41.4%, 24.2%, and 24.2% after re-resection and 32.2%, 12.4%, and 9.3% after RFA (p = 0.14). The 1-, 3-, and 5-year overall survival rates were 89.7%, 56.5%, and 35.2% after re-resection and 83.7%, 43.1%, and 29.1% after RFA (p = 0.48). For the second recurrence, 33.3% of patients underwent a second round of RFA and 10.0% underwent a third resection.ConclusionsThe two treatment modalities attained similar survival benefits in the management of recurrent HCC after hepatectomy. The high repeatability of RFA and that it can be delivered percutaneously render it a preferred treatment option for selected patients.

show abstract

Clinical significance of early hepatocellular carcinoma

Cited by 30 publications

References 24 publications

Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis

Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis

Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy

Survival Analysis of Re‐resection Versus Radiofrequency Ablation for Intrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma

Contact Info

Product

Resources

About